BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 10460901)

  • 1. Does the immunocytochemical detection of epithelial cells in bone marrow (micrometastasis) influence the time to biochemical relapse after radical prostatectomy?
    Weckermann D; Wawroschek F; Krawczak G; Haude KH; Harzmann R
    Urol Res; 1999 Aug; 27(4):285-90. PubMed ID: 10460901
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Does the immunocytochemical detection of epithelial cells in bone marrow (micrometastasis) influence the time to biochemical relapse after radical prostatectomy?
    Weckermann D; Wawroschek F; Krawczak G; Haude KH; Harzmann R
    Urol Res; 1999 Oct; 27(5):285-90. PubMed ID: 10644227
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disseminated cytokeratin positive tumor cells in the bone marrow of patients with prostate cancer: detection and prognostic value.
    Weckermann D; Müller P; Wawroschek F; Harzmann R; Riethmüller G; Schlimok G
    J Urol; 2001 Aug; 166(2):699-703. PubMed ID: 11458120
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low frequency epithelial cells in bone marrow aspirates from prostate carcinoma patients are cytogenetically aberrant.
    Mueller P; Carroll P; Bowers E; Moore D; Cher M; Presti J; Wessman M; Pallavicini MG
    Cancer; 1998 Aug; 83(3):538-46. PubMed ID: 9690547
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is preoperative serum prostate-specific antigen level significantly related to clinical recurrence after radical retropubic prostatectomy for localized prostate cancer?
    Haukaas SA; Halvorsen OJ; Daehlin L; Hostmark J; Akslen LA
    BJU Int; 2006 Jan; 97(1):51-5. PubMed ID: 16336328
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detection and prognostic value of cytokeratin positive tumor cells in bone marrow of patients with renal cell carcinoma.
    Buchner A; Riesenberg R; Kotter I; Crispin A; Hofstetter A; Oberneder R
    J Urol; 2003 Nov; 170(5):1747-51. PubMed ID: 14532768
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Disseminated tumor cells in bone marrow of patients with transitional cell carcinoma: immunocytochemical detection and correlation with established prognostic indicators.
    Hofmann T; Riesenberg R; Buchner A; Zimmermann W; Hofstetter A; Oberneder R
    J Urol; 2003 Apr; 169(4):1303-7. PubMed ID: 12629348
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Limitations of detection of bone-marrow micrometastasis in prostate carcinoma patients by CK18/PSA immunocytochemistry and PSA RT-PCR.
    Albers P; Ko Y; Wardelmann E; Schmidt D; Adam M; Vetter H; Müller SC
    Anticancer Res; 2000; 20(3B):2107-11. PubMed ID: 10928161
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic value of cytokeratin-positive bone marrow cells of gastric cancer patients.
    Gretschel S; Schick C; Schneider U; Estevez-Schwarz L; Bembenek A; Schlag PM
    Ann Surg Oncol; 2007 Feb; 14(2):373-80. PubMed ID: 17080240
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early postoperative peripheral blood reverse transcription PCR assay for prostate-specific antigen is associated with prostate cancer progression in patients undergoing radical prostatectomy.
    Shariat SF; Kattan MW; Song W; Bernard D; Gottenger E; Wheeler TM; Slawin KM
    Cancer Res; 2003 Sep; 63(18):5874-8. PubMed ID: 14522912
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Importance of tumor location in patients with high preoperative prostate specific antigen levels (greater than 20 ng/ml) treated with radical prostatectomy.
    Magheli A; Rais-Bahrami S; Peck HJ; Walsh PC; Epstein JI; Trock BJ; Gonzalgo ML
    J Urol; 2007 Oct; 178(4 Pt 1):1311-5. PubMed ID: 17698095
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer.
    Han M; Partin AW; Zahurak M; Piantadosi S; Epstein JI; Walsh PC
    J Urol; 2003 Feb; 169(2):517-23. PubMed ID: 12544300
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chromogranin A and biochemical progression-free survival in prostate adenocarcinomas submitted to radical prostatectomy.
    Alessandro S; Vincenzo G; Maria AG; Stefano S; Alessandro G; Salvatore M; Vincenzo T; Franco DS
    Endocr Relat Cancer; 2007 Sep; 14(3):625-32. PubMed ID: 17914093
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Urokinase-plasminogen-activator receptor expression in disseminated tumour cells in the bone marrow and peripheral blood of patients with clinically localized prostate cancer.
    Thomas C; Wiesner C; Melchior SW; Schmidt F; Gillitzer R; Thüroff JW; Pfitzenmaier J
    BJU Int; 2009 Jul; 104(1):29-34. PubMed ID: 19154451
    [TBL] [Abstract][Full Text] [Related]  

  • 15. No difference in six-year biochemical failure rates with or without pelvic lymph node dissection during radical prostatectomy in low-risk patients with localized prostate cancer.
    Bhatta-Dhar N; Reuther AM; Zippe C; Klein EA
    Urology; 2004 Mar; 63(3):528-31. PubMed ID: 15028451
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunocytochemical detection of occult tumor cells in the bone marrow: prognostic impact on early stages of lung cancer.
    Nosotti M; Tosi D; Palleschi A; Rosso L; Mendogni P; Santambrogio L
    Eur Surg Res; 2008; 41(3):267-71. PubMed ID: 18594145
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improved biochemical outcome with adjuvant radiotherapy after radical prostatectomy for prostate cancer with poor pathologic features.
    Vargas C; Kestin LL; Weed DW; Krauss D; Vicini FA; Martinez AA
    Int J Radiat Oncol Biol Phys; 2005 Mar; 61(3):714-24. PubMed ID: 15708249
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic significance of disseminated tumor cells in the bone marrow of prostate cancer patients treated with neoadjuvant hormone treatment.
    Köllermann J; Weikert S; Schostak M; Kempkensteffen C; Kleinschmidt K; Rau T; Pantel K
    J Clin Oncol; 2008 Oct; 26(30):4928-33. PubMed ID: 18794550
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Undetectable ultrasensitive PSA after radical prostatectomy for prostate cancer predicts relapse-free survival.
    Doherty AP; Bower M; Smith GL; Miano R; Mannion EM; Mitchell H; Christmas TJ
    Br J Cancer; 2000 Dec; 83(11):1432-6. PubMed ID: 11076649
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Update on Memorial Sloan-Kettering Cancer Center studies of neoadjuvant hormonal therapy for prostate cancer.
    Fair WR; Betancourt JE
    Mol Urol; 2000; 4(3):241-8;discussion 249-50. PubMed ID: 11062380
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.